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Many resource-poor countries are faced with concurrent epidemics of AIDS and tuberculosis (TB) caused by human immunode-
ficiency virus (HIV) and Mycobacterium tuberculosis, respectively. Dual infections with HIV and M. tuberculosis are especially
severe in infants. There is, however, no effective HIV vaccine, and the only licensed TB vaccine, the Mycobacterium bovis bacillus
Calmette-Guérin (BCG) vaccine, can cause disseminated mycobacterial disease in HIV-infected children. Thus, a pediatric vac-
cine to prevent HIV and M. tuberculosis infections is urgently needed. We hypothesized that a highly attenuated M. tuberculosis
strain containing HIV antigens could be safely administered at birth and induce mucosal and systemic immune responses to
protect against HIV and TB infections, and we rationalized that vaccine safety could be most rigorously assessed in immuno-
compromised hosts. Of three vaccine candidates tested, the recombinant attenuated M. tuberculosis strain mc26435 carrying a
simian immunodeficiency virus (SIV) Gag expression plasmid and harboring attenuations of genes critical for replication
(panCD and leuCD) and immune evasion (secA2), was found to be safe for oral or intradermal administration to non-SIV-in-
fected and SIV-infected infant macaques. Safety was defined as the absence of clinical symptoms, a lack of histopathological
changes indicative of M. tuberculosis infection, and a lack of mycobacterial dissemination. These data represent an important
step in the development of novel TB vaccines and suggest that a combination recombinant attenuated M. tuberculosis-HIV vac-
cine could be a safe alternative to BCG for the pediatric population as a whole and, more importantly, for the extreme at-risk
group of HIV-infected infants.
About one-third of the world’s population is infected with My-cobacterium tuberculosis (44). Every year, 8 to 10 million new
individuals become infected with M. tuberculosis and almost 1.5
million people die of tuberculosis (TB) (44). The recent develop-
ment of multidrug-resistant and extensively multidrug-resistant
strains of circulating M. tuberculosis further underscores the need
for novel approaches to combat TB. The only licensed TB vaccine,
bacillus Calmette Guérin (BCG), is a live attenuated vaccine de-
rived from Mycobacterium bovis. It is the oldest and most widely
used vaccine worldwide. Although the BCG vaccine can induce
potent cellular immune responses in infants and protect
against disseminated TB in children (22, 25, 41), the duration
of protection is questionable since immunity wanes with time
in many vaccinated individuals and the vaccine shows only
variable protection in adults (8, 29, 36). In addition, BCG vac-
cination offers little to no protection against pulmonary TB,
cannot eliminate latent M. tuberculosis, and is ineffective at
preventing subsequent TB.
TB is the leading cause of death in human immunodeficiency
virus (HIV)-infected individuals (43, 44). Given the large geo-
graphical overlap between M. tuberculosis and HIV infection, BCG
vaccination at birth was at one time recommended for all infants,
because infants with HIV-induced immune suppression have a
higher risk than adults of contracting TB (45). Recently, however,
it became apparent that the annual risk for disseminated BCG
disease in untreated HIV-infected infants (0.42%), associated
with a 75% mortality rate (12–14), clearly outweighs the potential
benefits of BCG vaccination in children with HIV (13). Therefore,
the WHO now advises against BCG vaccination of any infant in-
fected with HIV or at risk for HIV infection (46). As a result, the
number of infants coinfected with HIV and TB in resource-poor
countries is expected to remain the same or even rise.
Alternative methods to control TB in infants infected with HIV
are urgently needed. In response to this challenge, we aim to de-
velop a novel infant combination HIV-TB vaccine based upon a
safe, orally (p.o.) administrable attenuated M. tuberculosis strain
expressing HIV antigens. Although the rate of in utero and peri-
natal mother-to-child-transmission of HIV has been significantly
reduced with the introduction of antiretroviral therapy (ART) to
mother and/or child (43), breast milk transmission of HIV re-
mains a serious problem. Ideally, a vaccine to prevent p.o. HIV
acquisition by breast-feeding should be administered p.o. BCG-
based vaccines are advantageous because they can be administered
at birth, are effective when administered p.o., and rapidly generate
long-lived T cell responses against dually administered mycobac-
terial and coexpressed nonmycobacterial antigens when adminis-
tered to human infants (27).
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To address the safety concern associated with the current BCG
vaccine, we hypothesized that a rationally attenuated strain of hu-
man-adapted M. tuberculosis might be a better vaccine platform
than bovine-adapted M. bovis BCG. We developed auxotroph
mutants of human M. tuberculosis strain H37Rv in which myco-
bacterial genes important for replication and persistence were de-
leted or modified to attenuate replication. In addition, in an at-
tempt to increase immunogenicity, several genes important for
the evasion of host immune responses were deleted. The construc-
tion of these attenuated M. tuberculosis strains, their safety, and
their immunogenicity profiles in comparison to those of the li-
censed BCG vaccine in SCID mice have been reported previously
(16, 19, 28, 30–32). Some of these TB vaccine candidates were also
characterized in nonhuman primates as an important step toward
potential human clinical trials. Vaccine safety, immunogenicity,
and efficacy data obtained with nonhuman primates would be
expected to be highly relevant to humans (19). Attenuated M.
tuberculosis vaccine strains mc26020 and mc26030 were safe and
well tolerated in adult cynomolgus macaques and did not cause
TB but provided only partial protection against an intrabronchial
M. tuberculosis challenge (19). On the basis of these data, we de-
veloped novel, replication-attenuated M. tuberculosis vaccine
strains with increased immunogenicity.
Because of obvious ethical concerns, pediatric HIV-TB vaccine
safety assessments and challenge studies of efficacy cannot be per-
formed with HIV-infected human infants. To account for the in-
fant’s relatively inexperienced and still developing immune sys-
tem early after birth, we therefore chose to test vaccine safety in
infant macaques that show immune system ontogeny after birth
similar to that of human infants. In a first step toward the gener-
ation of a pediatric combination HIV-TB vaccine, we constructed
attenuated M. tuberculosis strains that express the simian immu-
nodeficiency virus (SIV) gag gene. The safety profiles of three dis-
tinct recombinant attenuated M. tuberculosis-SIV vaccine candi-
dates with different degrees of attenuation of replication and/or
immunogenicity (Table 1) were initially tested in healthy, non-
SIV-infected infant rhesus macaques. None of these vaccine can-
didates induced clinical symptoms of TB. The vaccine strain
(mc25157) that was attenuated predominantly for immune eva-
sion and less for replication caused M. tuberculosis dissemination
to multiple tissues and was therefore excluded as a potential pedi-
atric vaccine. The safety of the two other vaccine candidates, re-
combinant attenuated M. tuberculosis-SIV mc26020 and mc26435,
was then evaluated under even more stringent conditions with
immunosuppressed SIV-infected infant macaques, analogous to
HIV-infected human infants. The infant macaque model of SIV
infection is a well-established animal model of pediatric HIV in-
fection and is suitable for the testing of the safety and efficacy of
intervention strategies for a wide range of infectious diseases (1, 3,
4, 24, 38). Vaccination of SIV-infected infant macaques with these
two recombinant attenuated M. tuberculosis-SIV strains did not
cause TB-like lung pathology. Importantly, in animals vaccinated
with mc26435, local or systemic dissemination of mycobacteria
did not occur, and live mycobacteria could not be recovered from
any tissues under optimal culture conditions. The data represent
an important step in the clinical testing of these novel live atten-
uated M. tuberculosis vaccine candidates and suggest that a com-
bination recombinant attenuated M. tuberculosis-HIV vaccine
could be a safe alternative to BCG for the pediatric population as a
whole but more importantly for the extreme at-risk group of in-
fants infected with HIV.
MATERIALS AND METHODS
Animals. Newborn rhesus macaques (Macaca mulatta) from the SIV-
negative and type D retrovirus-free colony at the California National Pri-
mate Research Center (CNPRC; Davis, CA) were hand reared in a nursery.
Animals were housed according to the Guide for the Care and Use of Lab-
oratory Animals and the standards outlined by the American Association
for Accreditation of Laboratory Animal Care; all animal protocols were
reviewed and approved by the University of California at Davis Institu-
tional Animal Care and Use Committee prior to study initiation. Animals
were randomly assigned to the various study groups and were between 3
and 7 days of age at the first immunization (see Table 2). For vaccinations
and blood collections, animals were immobilized by intramuscular injec-
tion of ketamine-HCl (Parke-Davis, Morris Plains, NJ) at 10 mg/kg of
body weight. Trained veterinary staff monitored the animals daily for
clinical symptoms associated with TB (e.g., breathing difficulty, coughing,
increased mucus secretion, lethargic behavior, weight loss) and/or SIV
infection.
Vaccine strains and immunization regimens. The three recombinant
attenuated M. tuberculosis vaccine strains tested in the current study were
rationally attenuated from wild-type M. tuberculosis strain H37Rv. M.
tuberculosis H37Rv was modified through several deletions in genes sup-
porting replication to increase vaccine safety and in genes important for
mycobacterial immune evasion to enhance immunogenicity (5). As out-
lined in Table 1, strain mc26020 was predominantly attenuated for repli-
cation with deletions in the lysA and panCD loci (lysA panCD), no loci
important for immune evasion were deleted. We demonstrated previ-
ously that deletion of RD1 from M. tuberculosis H37Rv results in an atten-
uated strain with intermediate replication relative that of the parental
strain (30). Strain mc25157 was designed primarily to test for enhanced
immunogenicity (nuoG) with attenuation for intermediate replication
(panCD RD1) or no replication (leuCD panCD for mc26435). The
construction of the recombinant attenuated M. tuberculosis vaccine
strains has been previously described (19, 28, 31–33, 42, 49). In these prior
studies, the deletions introduced were stable and reversions were not ob-
served (19, 28, 31–33, 42, 49). Prior to their use in rhesus macaques, the
safety and immunogenicity of all three recombinant attenuated M. tuber-
culosis strains were confirmed in mice (19, 28, 31–33, 42, 49). The recom-




mc26020 (lysA panCD)a A, B lysA panCD (low)d None 19, 30-33, 42, 49
mc25157 (nuoG panCD RD1 pSIV Gag)b C–F panCD RD1 (intermediate) nuoG 28, 30
mc26435 (leuCD panCD secA2 pSIV Gag)c G–L leuCD panCD (low) secA2 28
a lysA panCD, deletions of the lysA and the panCD loci.
b nuoG panCD RD1, deletions of the nuoG, panCD, and RD1 loci; pSIV GAG, insertion of a full-length SIVmac239 Gag insert.
c leuCD panCD secA2, deletions of the leuCD, panCD, and secA2 loci.
d Replication levels are shown in parentheses.
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binant attenuated M. tuberculosis mc25157 and mc26435 vaccine strains
were further manipulated to incorporate a mycobacterial expression plas-
mid with a full-length SIVmac239 Gag insert (28). Expression of SIV Gag
in vaccine preparations was confirmed by Western blotting immunola-
beled with a horseradish peroxidase (HRP)-conjugated V5 antibody as
previously described (Fig. 1A) (28). Immunogenicity was confirmed in
C57BL/6 mice (Fig. 1B).
An overview of the vaccination schedule, including the route and dose,
is provided in Table 2. Briefly, strain mc26020 was administered both p.o.
and intradermally (i.d.) at 1 week of age and animals were followed up for
6 months (group A). Animals vaccinated with mc25157 were primed p.o.
and received a homologous i.d. booster vaccination at either 2 (group C)
or 3 (group E) weeks. Animals were euthanized at week 4 or 6, respec-
tively, to test for vaccine-induced immune responses and M. tuberculosis
dissemination in various tissues. The time intervals were selected on the
basis of our previous pathogenesis and pediatric HIV/SIV vaccine studies
in the infant macaque p.o. SIV infection model, in which we generally
challenge at 4 weeks of age to mimic early breast milk transmission of HIV
in humans (2, 23, 37, 38). Finally, we tested two heterologous prime-boost
regimens using either recombinant adenovirus 5 expressing SIVmac239
Gag (rAd5-SIVgag; groups G and H) or recombinant modified vaccinia
virus Ankara expressing SIVmac239 Gag, Pol, and Env (rMVA-SIVgpe;
group J) that were kindly provided by the International AIDS Vaccine
Initiative (Brooklyn, NY) and B. Moss (National Institute of Allergy and
Infectious Diseases [NIAID], NIH, Bethesda, MD), respectively (23). The
heterologous boosts were administered at 3 weeks (rAd5-SIVgag) or at 3
and 6 weeks (rMVA-SIV constructs) after the initial mc26435 vaccination.
In the studies described here, the vaccine boosts are reported solely for the
purpose of revealing all of the study variables; vaccine immunogenicity
will be reported separately (unpublished data). Note that all experiments
were carried out using parallel mock-infected (saline), age-matched in-
fant macaques as controls (Table 2, groups D, F, I, and K).
SIV infection. A subset of animals were infected with 103 50% tissue
culture infective doses of SIVmac251 (stock 6/04) (23) by the intravenous
(i.v.) route within 72 h of birth and then immunized 1 week later with
mc26020 (group B) or mc26435 (group L) (Table 2). SIV-infected animals
were euthanized when they met criteria established for retrovirus-infected
animals (40).
Sample collection and preparation. EDTA blood samples were col-
lected at week 0 (baseline) and then longitudinally as described in Table 2.
Plasma was collected after centrifugation and stored in multiple small
aliquots at 80°C for virological analysis and antibody testing. Peripheral
blood mononuclear cells (PBMC) were isolated by gradient centrifuga-
tion as described previously (23). At the time of euthanasia, multiple
tissues were collected, including tonsil, lymph node (LN; submandibular,
retropharyngeal, bronchial, axillary, and mesenteric), lung, and intestinal
tissues (ileum, colon). In addition, from animals that received an i.d.
vaccination, we saved tissue from the dermal inoculation site (groups A,
B, E, F, and I). Corresponding skin from p.o. vaccinated animals was
collected as control tissue. Each tissue sample was divided and saved for
multiple applications as follows: snap-frozen (M. tuberculosis culture),
formalin fixed and paraffin embedded (pathology, M. tuberculosis stain-
FIG 1 Vaccine-induced SIV-specific CD8 T cell responses in mice. (A)
Western blotting result showing SIVgag protein expression in mc26435 lysate
(lane 1) and its absence in mc26434 lysate expressing the control plasmid (lane
2). Lane 3 represents the molecular weight (MW) ladder. Recombinant atten-
uated M. tuberculosis whole-cell lysates were immunoblotted with HRP-con-
jugated anti-V5 antibodies and developed using chemiluminescence. The
principal recombinant SIVgag band migrates at approximately 55 kDa. One
lower-molecular-weight breakdown product is also observed in mc26435 ly-
sate. (B) C57BL/6 mice were immunized subcutaneously with 107 CFU of the
attenuated M. tuberculosis vaccine strain mc26434 (n  5) or with mc26434
that contained the SIV Gag expression cassette (named mc26435, n  5). One
week after immunization, splenocytes were isolated and AL11-SIVgag te-
tramer-specific CD8 T cell responses were determined by flow cytometric
analysis. Shown are the average percentages  standard deviations of AL11-
SIVgag tetramer-specific CD8 T cells. Note that mc26435-immunized mice
mounted AL11-SIVgag-specific CD8 T cell responses significantly higher
than those of mc26434-immunized mice (P  0.02), albeit the absolute fre-
quencies of tetramer-positive CD8 T cells were low.





















A 3 No mc26020 109, 106 p.o., i.d. 1 None 0, 2, 4, 6, 8, 10,
12, 16, 20, 24
24
B 3 Yes mc26020 109, 106 p.o., i.d. 1 None 0, 2, 4, 6 6
C 5 No mc25157 109 p.o. 0 mc25157 109 CFU i.d. 2 0, 2, 4 4
D 2 No Mock p.o., i.d. 0 Mock p.o., i.d. 2 0, 2, 4 4
E 5 No mc25157 109 p.o. 0 mc25157 109 CFU i.d. 3 0, 3, 6 6
F 2 No Mock p.o., i.d. 0 Mock p.o., i.d. 3 0, 3, 6 6
G 6 No mc26435 109 p.o. 0 rAd5SIV 9  109 PFU i.m.b 3 0, 3, 6, 9, 12, 16 16
H 6 No mc26435 106 i.d. 0 rAd5SIV 9  109 PFU i.m. 3 16
I 4 No Mock p.o., i.d. 0 Mock i.m. 3 16
J 8 No mc26435 109 p.o. 0 rMVASIV 108 PFU i.m. 3, 6 0, 3, 6, 9, 12, 16 18
K 3 No Mock p.o. 0 Mock i.m. 3, 6 16
L 3 Yes mc26435 109 p.o. 1 None 0, 1, 2, 4, 6, 8, 10 6–10
a Number of animals.
b i.m., intramuscular.
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ing), and made into fresh tissue aliquots (immunogenicity). The isolation
of cell populations from tonsil, LN, and intestinal tissues was performed
as described previously (23).
CD4 T cell measurement. A complete blood count (CBC) was per-
formed on an ABX Pentra 60 electronic cell counter (ABX Diagnostics,
Irvine, CA) with manual differential counts. Absolute counts and percent-
ages of CD4 T cells in PBMC were determined using antibodies specific
for rhesus macaque CD3 and CD4 by flow cytometric analysis and CBC
values as described previously (2).
SIV replication. Plasma samples were analyzed for viral RNA by a
quantitative reverse transcription-PCR assay as previously described (7).
M. tuberculosis-specific plasma antibodies. The presence of IgG an-
tibodies against the M. tuberculosis PSTS1 antigen in longitudinally col-
lected plasma samples was determined by using a recently described mul-
tiplex microbead immunoassay based on the Luminex system (Luminex
Corp., Austin, TX) (17). Each sample was tested in duplicate. Relative
antibody levels are reported as mean fluorescence intensities (MFIs) (17).
Sera from non-M. tuberculosis-infected and M. tuberculosis-infected rhe-
sus macaques were used as negative and positive controls, respectively.
Pathology evaluation. Gross pathology evaluation was performed at
necropsy. Formalin-fixed, paraffin-embedded tissues were cut into 5-	m
sections and stained with hematoxylin and eosin (H&E) according to
standard protocols. Lung sections from an adult macaque infected exper-
imentally with virulent M. tuberculosis were kindly provided by P. Luciw
for comparison (21). In addition, Ziehl-Neelsen-stained sections were
examined for the presence of acid-fast bacilli (AFB). Tissue section slides
were read in their entirety by a veterinary pathologist blinded with respect
to treatment groups.
M. tuberculosis isolation. Snap-frozen tissues, stored at 80°C, were
shipped to the National Animal Disease Center (USDA-ARS, Ames, IA) to
recover viable mycobacteria using three different culture methods, (i)
the fast indicator tube test (MGIT), (ii) Middlebrook 7H12 medium
(BacTec), and (iii) solid culture medium, to determine CFU counts. As
recombinant attenuated M. tuberculosis auxotrophic mutants cannot
grow in a standard mycobacterial growth medium culture, the medium
was supplemented with pantothenate with or without lysine (mc26020) or
leucine (mc26435). A tissue was considered positive if one of three culture
methods yielded mycobacterial growth. M. tuberculosis positive-control
samples were run in parallel for quality assurance.
Statistical analysis. Data were analyzed using GraphPad Prism soft-
ware (GraphPad Software, Inc., La Jolla, CA). Antibody data at specific
time points (see the text) were compared between two or more groups
after log10 transformation using a nonparametric Mann-Whitney test or
one-way analysis of variance (Kruskal-Wallis test with Dunn’s compari-
sons), respectively. Area-under-the-curve analysis of antibody levels was
also performed on log10-transformed data using GraphPad Prism Soft-
ware. P values of 0.05 were considered significant.
RESULTS
Confirmation of vaccine exposure by the p.o. and i.d. routes. All
three vaccine strains were attenuated for replication. We therefore
wanted to confirm that they were able to induce seroconversion to
validate the biological significance of our safety assessment that
includes lack of mycobacterial dissemination in an immunocom-
promised host. Plasma antibodies to the M. tuberculosis-specific
antigen PSTS1 were measured after p.o. and i.d. vaccination with
the various recombinant attenuated M. tuberculosis vaccines. In-
dependent of the vaccine strain, all non-SIV-infected vaccinated
animals developed M. tuberculosis-specific plasma IgG antibodies
to the PSTS1 antigen (Fig. 2), but the magnitude was dependent
on the vaccine strain and the route of administration. Animals
that received the mc26020 vaccine via the p.o. and i.d. routes at 1
week of age (group A) developed relative antibody levels of up to
104 MFI by 4 weeks (Fig. 2A). Similar data were obtained with
animals primed p.o. with mc25157 and given a homologous i.d.
boost (groups C and E; Fig. 2B). Consistent with more stringent
attenuation of replication (deletions of the leuCD and panCD
loci), in animals vaccinated p.o. with the mc26435 vaccine strain
(groups G and J), PSTS1 antibody levels were significantly lower
(P  0.001) during weeks 4 to 6 postimmunization than those in
mc26020- and mc25157-vaccinated infant macaques. Further-
more, the route of vaccine administration influenced the magni-
tude of antibody induction in plasma, with i.d. mc26435-vacci-
nated animals (group H) developing significantly higher (P 
0.0119) antibody levels than p.o. vaccinated animals (groups G
and J). Although there was a trend toward higher PSTS1 antibody
levels in p.o. mc26435-vaccinated infants than in mock-immu-
nized animals between weeks 5 and 8 postvaccination, this differ-
ence did not reach statistical significance. PSTS1 antibody levels,
however, were significantly higher in mc26435-vaccinated infants
than in mock-immunized animals by area-under-the curve-anal-
ysis of antibody levels from week 0 to week 16 (P  0.0229). The
PSTS1 antibody levels in animals infected with SIV prior to vacci-
nation with recombinant attenuated M. tuberculosis mc26020
FIG 2 M. tuberculosis-specific plasma IgG antibody responses. Plasma antibody responses to PSTS1 antigen were measured by multiplex microbead array
analysis. Average antibody levels plus standard deviations for mock-vaccinated animals (black lines, closed circles), SIV-infected and vaccinated animals (red
lines, diamonds), and non-SIV-infected vaccinated animals (blue lines, triangles) are shown for each vaccine candidate. Data are reported as MFIs. The
experimental groups are listed in parentheses in the top right corner of each panel. The mock-vaccinated animals used for groups A and B are the same animals
used as controls for groups G, H, J, and L. Note that in panel A, one of three non-SIV-infected vaccinated animals had high PSTS1 antibody levels at day 0 (MFI
of 666 compared to MFIs of 40 and 18 in the other remaining animals, and therefore, the average baseline antibody levels at day 0 appear higher than those of
groups B, I, and K. Similarly, in panel C, 2 of 6 animals vaccinated i.d. and 2 of 14 animals vaccinated p.o. with mc26435 had PSTS1 MFIs (antibody levels) of 
100
at day 0, explaining the higher MFI values at day 0 than those of groups I, K, and L.
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(group B) or mc26435 (group L) were lower than those of non-
SIV-infected animals (Fig. 2A and C), likely because of SIV-in-
duced immunosuppression.
Safety assessment of recombinant attenuated M. tuberculo-
sis-SIV vaccine strains. The safety profile of the various recombi-
nant attenuated M. tuberculosis vaccine strains was evaluated on
the basis of a combination of (i) clinical observations (e.g., breath-
ing difficulties), (ii) histopathological evaluation of multiple tis-
sues, (iii) detection of AFB in tissues, and (iv) recovery of viable
mycobacteria from tissues. A vaccine was considered to have no or
only a minimal safety risk if AFB could not be detected, mycobac-
terial bacilli could not be recovered from any tissues, histopathol-
ogy of lung and other tissues/organs appeared essentially normal,
and no clinical symptoms were observed. In contrast, a vaccine
strain was considered unsafe if one or more tissues were AFB pos-
itive, M. tuberculosis culture positive, or granuloma positive dur-
ing histopathological examination.
We assessed the safety of the recombinant attenuated M. tuber-
culosis vaccine strains in a stringent two-step study. First, the re-
combinant attenuated M. tuberculosis vaccine strains were admin-
istered to immunologically immature infant macaques at 1 week
of age. Next, if no clinical signs of M. tuberculosis infection were
observed and no viable mycobacteria could be recovered from
tissues, we tested the vaccine in infant macaques infected with
highly pathogenic SIVmac251 at 1 week prior to recombinant
attenuated M. tuberculosis vaccination as a model of HIV-induced
immunosuppression in HIV-1-infected human infants.
(i) Clinical safety assessment. SIV infection (groups B and L)
was confirmed by measuring plasma viral RNA levels. Consistent
with our prior studies (2, 23, 38, 39), all six infant macaques de-
veloped high peak viremia (
107 copies/ml of plasma) (Fig. 3A)
which persisted at high levels. The loss of CD4 T cells is a hall-
mark of HIV/SIV disease progression in adults but not a reliable
clinical marker of virus-infected infants (2). Furthermore, as
CD4 T cells represent the vast majority of T cells at birth, and
CD8 T cell numbers continue to increase after birth, a decline in
the percentage of CD4 T cells is characteristic of the normal
developmental process after birth. In fact, a decline in CD4 T
FIG 3 Plasma SIV viremia and clinical parameters. (A) Numbers of SIV RNA copies per milliliter of plasma in samples longitudinally collected from each
animal are shown. Each symbol represents an individual animal. The experimental group of each animal is shown in parentheses. (B) The average increase
in weight over the birth weight (kilograms) is shown for the animals in each of the three vaccine groups (dark blue, yellow, and light blue lines) and for
SIV-infected and subsequently vaccinated animals (red line) in comparison to the weight gain of mock-vaccinated animals (gray line). The averages of
absolute numbers  standard deviations (C) and average percentages  standard deviations of CD4 T cells (D) in peripheral blood are shown for
animals vaccinated after prior SIV infection (red lines, diamonds) and for vaccinated non-SIV-infected (blue lines, triangles) animals in comparison to
mock-vaccinated animals (black lines, circles). Note that panels C and D include the SIV-infected animals vaccinated with mc26020 (n  3) or mc26435
(n  3). For this analysis, vaccinated animals (n  33) included animals from groups A, C, E, G, H, and J and mock-vaccinated animals (n  11) included
animals from groups D, F, I, and K.
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cells was observed in all experimental groups and was not limited
to only SIV-infected infants (2) (Fig. 3). Compared to age-
matched control animals (mock-vaccinated animals), non-SIV-
infected vaccinated animals showed similar peripheral blood
CD4 T cell frequencies. In addition, the CBC values in non-SIV-
infected, recombinant attenuated M. tuberculosis-vaccinated in-
fants remained normal throughout the study period (data not
shown).
A more critical factor in the evaluation of infant health is
weight gain. All vaccinated non-SIV-infected infants showed a
weight gain similar to that of age-matched control animals (Fig.
3). In contrast, consistent with previous studies (2, 24), SIV-in-
fected animals showed poor weight gain (Fig. 3). Although wast-
ing is also a common symptom of HIV/SIV-associated disease in
adults (10), the lack of weight gain is much more detrimental in
infants. Due to a failure to thrive and symptoms associated with
rapid progression to simian AIDS (e.g., recurring episodes of di-
arrhea, poor appetite, and lethargic behavior), the SIV-infected
animals were euthanized between 6 and 10 weeks after SIV infec-
tion (Fig. 3). Despite this apparent immunosuppression as a result
of SIV infection, these animals did not show clinical symptoms
typically associated with M. tuberculosis infection. Non-SIV-in-
fected infants that received the mc26020 or mc26435 vaccine
(group A or groups G, H, and J, respectively) showed normal
weight gain (Fig. 3).
Clinically, no symptoms indicative of M. tuberculosis infection
(e.g., breathing difficulties, coughing) were observed at any time
during the study period. Similarly, no adverse signs of vaccination
with recombinant attenuated M. tuberculosis-SIV vaccines were
observed, with the exception of local reactivity in i.d. vaccinated
animals. These animals showed a local inflammatory response
following i.d. inoculations and developed indurations. In
mc26020-vaccinated animals, the indurations resolved over time.
Due to the short follow-up time in mc25157-vaccinated animals, it
could not be determined whether the local inflammation would
have resolved over time.
(ii) Histopathological evaluation. To thoroughly assess the
safety of the recombinant attenuated M. tuberculosis vaccine
strains in infants, we evaluated several tissues collected at necropsy
for TB pathology, i.e., (i) the dermal inoculation site or corre-
sponding skin samples from p.o. recombinant attenuated M. tu-
berculosis- or mock-vaccinated animals, (ii) axillary LNs that
drained the dermal inoculation site, (iii) the lung as the primary
site of TB-specific pathology, (iv) the lung-draining bronchial
LNs, and (v) the spleen as a more distal lymphoid indicator of M.
tuberculosis dissemination (Table 3).
Consistent with clinical signs of inflammation (see above), his-
topathological examination of mc25157-vaccinated animals at 4
or 6 weeks of age (groups C and E, respectively) revealed that
moderate-to-severe pyogranulomatous dermatitis had persisted
at the i.d. inoculation sites, whereas dermal tissues from mc26020-
vaccinated animals appeared essentially normal (Table 3). In con-
trast to vaccination with mc26020 and mc25157, i.d. vaccination
with mc26435 (group H) did not result in an inflammatory re-
sponse at the site of inoculation (Table 3). The mild dermatitis
that was observed in some of the vaccinees independent of the
vaccine strain was occasionally noted in skin from p.o. or mock-
vaccinated animals as well and thus was probably not due to vac-
cination (Table 3). Consistent with a potential spread of mycobac-
teria in mc25157-vaccinated animals (groups C and E), the
majority of the axillary LNs of mc25157-vaccinated animals
showed moderate lymphoid hyperplasia and pyogranulomatous
inflammation, whereas non-SIV-infected animals vaccinated with
mc26020 or mc26435 showed only mild histopathological changes
(Table 3). Evidence of pulmonary TB lesions or granuloma for-
mation in the lung indicative of M. tuberculosis infection was
markedly absent from the vaccinated animals. In fact, the lungs of
animals vaccinated with mc26020 (not shown) and mc26435 (Fig.
4E) were histologically indistinguishable from the lungs of mock-
vaccinated infant macaques (Fig. 4C). Of the 10 animals vacci-
nated with mc25157, 6 developed small granulomas in their lungs
(Fig. 4D). However, these lesions were smaller and less frequent
than the granulomas induced by virulent M. tuberculosis infection
(Fig. 4A and B).
In infants infected with SIV prior to recombinant attenuated
M. tuberculosis vaccination, histopathological changes typical of
SIV infection, such as mild lymphoid hyperplasia or subsequent
lymphoid depletion, were commonly observed in various lym-
phoid tissues (Table 3). Although pneumonitis was detected in
some SIV-infected, recombinant attenuated M. tuberculosis-vac-
cinated animals, the histopathology was not typical of M. tubercu-
losis-induced lung pathology. Importantly, SIV-infected animals
did not develop granulomas in the lung or other tissues after vac-
cination with mc26020 or mc26435 (Fig. 4F). Thus, SIV-induced
immunosuppression in infant macaques vaccinated with recom-
binant attenuated M. tuberculosis strains did not result in TB-
induced disease or pathology.
(iii) Strain-dependent differences in mycobacterial dissemi-
nation. Miliary tuberculosis is one of the most severe complica-
tions of M. tuberculosis infection. Although the recombinant at-
tenuated M. tuberculosis vaccine strains tested in the current study
were replication attenuated, the degree of attenuation of replica-
tion and immune evasion differed between the strains (Table 1).
Therefore, we tested the same tissues that were examined for TB-
associated pathology for the presence of mycobacteria. First, tissue
sections were stained with the Ziehl-Neelsen stain to detect AFB.
However, even in pathogenic M. tuberculosis infection, detection
of mycobacteria by AFB staining can be infrequent. Therefore,
different culture methods using optimized growth medium spe-
cially supplemented for the auxotrophic strains were used to de-
termine whether live mycobacteria could be recovered from any of
the tissues. AFB were only rarely (1 or 2 bacilli per tissue), if at all,
detected at dermal inoculation sites after mc26020 or mc26435
vaccination. Importantly, AFB were detected in tissue from only
one of three SIV-infected infant macaques that received the
mc26020 vaccine and only at one site, the axillary LN which
drained the i.d. inoculation site. AFB were not detected by Ziehl-
Neelsen staining in any other tissues of this animal. Live mycobac-
teria could be recovered from the same axillary LN of this animal
but not from any other tissue samples. In contrast, all infant ma-
caques vaccinated with mc25157, the recombinant attenuated M.
tuberculosis vaccine strain that contained deletions that may in-
crease its immunogenicity and yet result in replication higher than
that of mc26020, tested positive for AFB in their dermal tissues,
and in 6 of 10 animals, AFB were also detected in at least one other
tissue type (Table 4). Furthermore, live mycobacteria could be
recovered from several tissues of these animals (Table 4). Due to
the widespread mycobacterial dissemination and more severe im-
munopathology in mc25157-vaccinated infant macaques, strain
mc25157 was considered unsafe and not further pursued as a can-
Pediatric HIV-TB Vaccine Safety in Infant Macaques
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didate M. tuberculosis-SIV vaccine. Remarkably, all tissues from
non-SIV-infected (n  20) and also from SIV-infected (n  3),
mc26435-vaccinated animals were negative for AFB, and viable
mycobacteria could not be recovered from any of these tissues by
any of the culture methods used.
In summary, the data indicate that recombinant attenuated M.
tuberculosis-SIV vaccine strains can be administered p.o. or i.d. to
infant macaques during the first postnatal week. Although vaccine
strain mc25157 caused dissemination of mycobacteria, the live
attenuated vaccine strains mc26020 and mc26435 demonstrated a
better safety profile in infant macaques. In particular, strain
mc26435 was safe in non-SIV-infected (groups I and K) and in
immunocompromised, SIV-infected infant macaques (groups G,
H, and J) by all of the safety criteria used in this study.
DISCUSSION
An effective vaccine against HIV is not available, and the only
approved TB vaccine, BCG, is not safe in immunosuppressed in-
dividuals. This safety concern is of particular importance in re-
source-poor countries affected by the dual epidemics of TB and
AIDS. In particular, TB infection rates among children have risen
in association with HIV prevalence, and about 1% of HIV-in-
fected infants develop disseminated BCG disease after vaccina-
tion. Although ART coverage now extends to 42% of HIV-in-
fected mothers, only about 23% of their newborn infants receive
ART (43, 45) and the rest remain at risk for HIV acquisition by
breast-feeding. These facts underscore the need for a novel safe
vaccine to prevent pediatric HIV and TB infections. The current
study represents an important first step toward the development
of a p.o. administered highly attenuated M. tuberculosis vaccine
expressing HIV antigens as a potential pediatric combination
HIV-TB vaccine.
BCG was originally administered p.o., but this route was
discontinued due to cervical lymphadenitis and parapharyn-
geal complications. The p.o. route may be more advantageous
FIG 4 Pathology evaluation of lung tissue. Formalin-fixed, paraffin-embedded tissues were stained with H&E and blindly analyzed for histological changes due
to vaccination and/or SIV infection. (A) Lung tissue (magnification, 100) of an adult rhesus macaque infected with pathogenic M. tuberculosis (21). (B) The
same tissue shown in panel A at 200 magnification. Note the central necrosis, mineralization, and granuloma formation and the presence of multinucleate giant
cells. (C) Lung section of a mock-immunized infant macaque. (D) Representative lung section of an mc25157-vaccinated infant macaque with granulomatous
tissue and signs of extensive atelectasis. Panels E and F show essentially normal lung sections from non-SIV-infected (E) or SIV-infected (F) infant macaques after
mc26435 vaccination. The sections in panels C to F are at 100 magnification.
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for a pediatric HIV-TB vaccine, because a mucosally adminis-
tered vaccine could also induce local immune responses pro-
tective against HIV transmitted p.o. by breast-feeding. In fact,
experiments with mice have shown that p.o. fed BCG can infect
the submandibular lymph nodes and Peyer’s patches (18) and
that M. tuberculosis can bind to tonsillar M cells (6, 26). Thus,
we assessed the safety of three distinct recombinant attenuated
M. tuberculosis H37Rv strains, engineered with or without the
SIV gag gene, in non-SIV-infected and in SIV-infected, and
thus immunosuppressed, infant macaques by the p.o. and i.d.
routes. BCG vaccination of SIV-infected macaques has previ-
ously been shown to exacerbate SIV disease progression and to
cause dissemination of M. bovis bacilli (9, 35, 48). In accor-
dance with a recent proposal to improve the classification of TB
disease severity in human children by combining multiple fac-
tors ranging from disease pathogenesis criteria to bacteriolog-
ical evaluation and clinical data (47), vaccine safety in infant
macaques was rigorously assessed in the current study by com-
prehensive clinical examination, histopathological evaluation,
and multiple M. tuberculosis culture methods.
For safety evaluation, animals were grouped by vaccine
strain independent of the route of administration, immuniza-
tion interval, or prime-boost regimen. The panCD deletion in
strain mc25157 was not sufficient to prevent mycobacterial dis-
semination in infant macaques, and although granuloma size
and frequency in the lung were limited in comparison to those
of animals infected with pathogenic TB (21), the strain was
deemed unsuitable for use in immunocompromised hosts. In
contrast to the safety profile of mc25157, that of dual deletion
strain mc26020 (panCD lysA) was improved. Only one of
three SIV-infected infant rhesus macaques showed evidence of
M. tuberculosis dissemination, and only in the axillary lymph
node that drained the i.d. inoculation site. Whether or not this
limited mycobacterial dissemination in immunosuppressed
SIV-infected infant macaques correlates with a reduced risk of
future dissemination or reactivation at other sites, however,
TABLE 4 M. tuberculosis detection
Group(s) (strain), no.
of animals, tissue type AFB
MGITa BacTecb Solid culturec
Result           
A (mc26020), 3
Skin 0/3 NTd NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
B (SIV  mc26020), 3
Skin 0/3 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 1/3e 2/3 1/3 0/3 0/3 2/3 1/3 0/3 0/3 3/3 0/3 0/3 0/3 1/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
C, E (mc25157), 10
Skin 10/10 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 2/10 4/10 1/10 3/10 2/10 5/10 0/10 3/10 2/10 5/10 1/10 3/10 1/10 5/10
Lung 1/10 5/10 1/10 1/10 3/10 3/10 5/10 1/10 1/10 5/10 1/10 1/10 3/10 7/10
Axillary LN 5/10 2/10 1/10 3/10 4/10 2/10 3/10 2/10 3/10 3/10 1/10 3/10 3/10 8/10
Spleen 0/10 0/10 5/10 5/10 0/10 0/10 10/10 0/10 0/10 0/10 4/10 4/10 2/10 10/10
G, H, J (mc26435), 20
Skin 0/20 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Lung 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Axillary LN 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
Spleen 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 20/20 0/20 0/20 0/20 0/20
L (SIV  mc26435), 3
Skin 0/3 NT NT NT NT NT NT NT NT NT NT NT NT NT
Bronchial LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Lung 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Axillary LN 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
Spleen 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 3/3 0/3 0/3 0/3 0/3
a MGIT results: , no growth; , 24 days; , 18 to 24 days; , 18 days.
b BacTec results: , no growth; , 24 days; , 18 to 24 days; , 18 days.
c Solid culture results: , no growth; , 5 CFU; , 5 to 50 CFU; , 50 CFU.
d NT, not tested.
e Samples positive for AFB or outgrowth of mycobacteria are in bold.
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remains to be determined. Although we previously confirmed
the safety of this strain, these studies were performed only with
non-SIV-infected adult cynomolgus macaques (19). Thus, the
current data support our hypothesis that auxotroph mutant M.
tuberculosis strains can be developed as safe vaccine candidates
for use in immunocompromised individuals. M. tuberculosis is
a slowly replicating bacterium with genes that limit the host
immune response, permitting bacilli to persist within a host,
often in a latent state (11, 20). To be safe and effective, a live
attenuated M. tuberculosis vaccine requires a balance between
replication and immunogenicity. In infants with immature im-
munity, low-level replication may be required to induce M.
tuberculosis-specific immune responses and promote persistent
immune memory responses. However, if replication is too ro-
bust, attenuated M. tuberculosis strains may result in granu-
loma formation and bacillary dissemination, as was observed
with mc25157. In addition to attenuating replication, deletions
in mycobacterial genes that encode immune interference may
be necessary to enhance attenuated M. tuberculosis immunoge-
nicity.
On the basis of the results obtained with mc25157 and
mc26020, strain mc26435 was designed with deletions of both the
panCD and leuCD loci (panCD leuCD). An additional deletion
was introduced into the secA2 locus that interferes with apoptosis
in M. tuberculosis-infected macrophages (5, 15). The deletion of
this locus has been associated with both enhanced apoptosis of
mycobacterium-infected macrophages in vitro and with increased
antigen-specific CD8 T cell responses in vivo, the latter likely due
to enhanced cross-presentation of mycobacterial antigens to den-
dritic cells (5, 15). A similar attenuated M. tuberculosis strain
(lysA secA2) has previously been demonstrated to be safe and
immunogenic in neonatal SCID mice (100% survival for up to 642
days), in which BCG is generally lethal (28). Our results here show
that recombinant attenuated M. tuberculosis strain mc26435 was
well tolerated by and did not cause any TB-like disease in 20 infant
macaques vaccinated within the first week of life. Importantly, the
safety of this strain was confirmed in infant macaques infected
with highly pathogenic SIV prior to mc26435 vaccination. The
tissue pathology of these SIV-infected infant macaques was con-
sistent only with SIV infection with no signs of M. tuberculosis
infection. Furthermore, there was no histopathological evidence
of recombinant attenuated M. tuberculosis dissemination, and live
mycobacteria could not be recovered from any of the tissues stud-
ied, even under optimal supplemented culture conditions for the
attenuated M. tuberculosis strain.
No other TB vaccine candidate has been tested under such
stringent conditions in infant macaques, a model of human infant
TB vaccination. Analogous to our study, the safety of a leuCD
panCD auxotroph M. tuberculosis vaccine strain was recently
evaluated in non-SIV-infected and SIV-infected adult macaques
(34). Vaccination of adult macaques with this attenuated M. tu-
berculosis strain did not cause adverse effects, AFB were not de-
tectable, and viable mycobacterial bacilli could not be recovered
from longitudinally collected blood samples or tissues collected at
euthanasia (34). The adult SIV-infected animals were followed up
for up to 1 year, further supporting the conclusion that auxotroph
attenuated M. tuberculosis strains do not pose a safety risk to im-
munosuppressed individuals. The safety profile of recombinant
attenuated M. tuberculosis strain mc26435 in SIV-infected infant
macaques is consistent with this conclusion.
A potential caveat of our study is the relatively short follow-up
time of SIV-infected infants. In HIV-infected children and SIV-
infected neonatal macaques, disease is often more severe and pro-
gression is accelerated. In the current study, SIV-infected infants
were euthanized between 6 and 10 weeks after SIV infection be-
cause of a failure to thrive. Therefore, vaccine-induced M. tuber-
culosis-associated pathology or dissemination had to manifest it-
self within a relatively short time period in SIV-infected animals to
be detected and we cannot draw any conclusions about the long-
term outcome. It should be emphasized, though, that M. tubercu-
losis dissemination was observed in multiple infant tissues col-
lected at 4 or 6 weeks after vaccination with mc25157 by
pathology, histology, and culture assays. The latter data imply that
lung pathology and M. tuberculosis dissemination should be de-
tectable within a 10-week time frame, especially in immunosup-
pressed SIV-infected animals.
To our knowledge, this is the first study demonstrating that an
attenuated M. tuberculosis strain does not cause disease in an in-
fant nonhuman primate model of neonatal TB vaccination and
SIV infection that is highly relevant to human infants, including
those at risk for perinatal HIV infection. Our data show that all
three vaccines were able to induce persistent vaccine-specific an-
tibody responses in infant macaques, albeit the magnitude was
dependent on the level of replication attenuation (mc26020 
mc25157 
 mc26435) and the route of vaccine administration
(i.d. 
 p.o.). The persistence of these antibodies suggests that the
recombinant attenuated M. tuberculosis vaccines primed the in-
fant immune system. Despite the low plasma M. tuberculosis-spe-
cific PSTS1 antibody responses after p.o. and i.d. administration
in infant rhesus macaques, recombinant attenuated M. tuberculo-
sis vaccine strain mc26435 (which contains a mycobacterial ex-
pression plasmid encoding SIV Gag) was effective at inducing
both SIV- and TB-specific CD4 and CD8 T cell immune re-
sponses in systemic and mucosal tissues (unpublished data).
Therefore, recombinant attenuated M. tuberculosis strain
mc26435 should be further explored and optimized as a valid TB
vaccine candidate that could replace BCG, as well as function as a
combination vaccine to protect infants against both HIV and TB
infections. Considering that immune correlates of protection
against HIV or TB acquisition are not well defined, these vaccines
ultimately need to be tested for efficacy against an HIV/SIV and M.
tuberculosis challenge.
ACKNOWLEDGMENTS
The studies reported here were supported by NIH NIDCR 1R01
DE019064 to K.A., M.H.L., and G.F. K.J. was supported by the NIAID/
Department of Health and Human Services training grant Molecular Bi-
ology of Viral Diseases (T32 AI007419). In addition, K.A. and K.J. were
supported by the CFAR at UNC-Chapel Hill (R01 AI50410; NIH/NIAID).
The animal studies at the CNPRC were supported by grant RR00169 from
the National Center for Research Resources (NCRR; NIH). SIVmac251
was obtained from the Analytical and Resource Core of the CNPRC. The
SIVgag peptide pool was provided by the NIH AIDS Research and Refer-
ence Reagent Program (Division of AIDS, NIAID, NIH).
We thank the Quantitative Molecular Diagnostics Core of the AIDS
Vaccine Program, SAIC Frederick, Inc., National Cancer Institute,
Frederick, Frederick, MD, for assistance with viral RNA load determi-
nations. We are indebted to Suelee Robbe Austerman at the USDA-
ARS, Ames, IA, for performing the M. tuberculosis culture testing. In
addition, we thank the Colony Services; the Pathology, Veterinary and
Pediatric HIV-TB Vaccine Safety in Infant Macaques
August 2012 Volume 19 Number 8 cvi.asm.org 1179
Clinical staff at the CNPRC; and Yongzhi Geng for technical assistance
in these studies.
The contents of this publication are solely our responsibility and do
not necessarily represent the official views of NCRR or NIH.
REFERENCES
1. Abel K. 2009. The rhesus macaque pediatric SIV infection model—a
valuable tool in understanding infant HIV-1 pathogenesis and for design-
ing pediatric HIV-1 prevention strategies. Curr. HIV Res. 7:2–11.
2. Abel K, et al. 2006. Rapid virus dissemination in infant macaques after
oral simian immunodeficiency virus exposure in the presence of local
innate immune responses. J. Virol. 80:6357– 6367.
3. Amedee AM, Lacour N, Ratterree M. 2003. Mother-to-infant transmis-
sion of SIV via breast-feeding in rhesus macaques. J. Med. Primatol. 32:
187–193.
4. Amedee AM, Rychert J, Lacour N, Fresh L, Ratterree M. 2004. Viral and
immunological factors associated with breast milk transmission of SIV in
rhesus macaques. Retrovirology 1:17.
5. Baena A, Porcelli SA. 2009. Evasion and subversion of antigen presenta-
tion by Mycobacterium tuberculosis. Tissue Antigens 74:189 –204.
6. Brandtzaeg P. 1999. Regionalized immune function of tonsils and ade-
noids. Immunol. Today 20:383–384.
7. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV
plasma viral load assay: practical considerations, realistic performance
expectations, and application to reverse engineering of vaccines for AIDS.
J. Med. Primatol. 34:303–312.
8. Colditz GA, et al. 1994. Efficacy of BCG vaccine in the prevention of
tuberculosis. Meta-analysis of the published literature. JAMA 271:698 –
702.
9. Croix DA, et al. 2000. Effect of mycobacterial infection on virus loads and
disease progression in simian immunodeficiency virus-infected rhesus
monkeys. AIDS Res. Hum. Retroviruses 16:1895–1908.
10. Freeman LM, et al. 2004. Body-composition changes in the simian im-
munodeficiency virus-infected juvenile rhesus macaque. J. Infect. Dis.
189:2010 –2015.
11. Gill WP, et al. 2009. A replication clock for Mycobacterium tuberculosis.
Nat. Med. 15:211–214.
12. Hesseling AC, et al. 2009. Disseminated bacille Calmette-Guérin disease
in HIV-infected South African infants. Bull. World Health Organ. 87:505–
511.
13. Hesseling AC, et al. 2007. The risk of disseminated bacille Calmette-
Guérin (BCG) disease in HIV-infected children. Vaccine 25:14 –18.
14. Hesseling AC, et al. 2006. Bacille Calmette-Guérin vaccine-induced dis-
ease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42:
548 –558.
15. Hinchey J, et al. 2007. Enhanced priming of adaptive immunity by a
proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117:
2279 –2288.
16. Jacobs M, Fick L, Allie N, Brown N, Ryffel B. 2002. Enhanced immune
response in Mycobacterium bovis bacille Calmette Guérin (BCG)-
infected IL-10-deficient mice. Clin. Chem. Lab. Med. 40:893–902.
17. Khan IH, et al. 2008. Profiling antibodies to Mycobacterium tuberculosis
by multiplex microbead suspension arrays for serodiagnosis of tuberculo-
sis. Clin. Vaccine Immunol. 15:433– 438.
18. Lagranderie M, Chavarot P, Balazuc AM, Marchal G. 2000. Immuno-
genicity and protective capacity of Mycobacterium bovis BCG after oral or
intragastric administration in mice. Vaccine 18:1186 –1195.
19. Larsen MH, et al. 2009. Efficacy and safety of live attenuated persistent
and rapidly cleared Mycobacterium tuberculosis vaccine candidates in
non-human primates. Vaccine 27:4709 – 4717.
20. Lin PL, Flynn JL. 2010. Understanding latent tuberculosis: a moving
target. J. Immunol. 185:15–22.
21. Luciw PA, et al. 2011. Stereological analysis of bacterial load and lung
lesions in nonhuman primates (rhesus macaques) experimentally infected
with Mycobacterium tuberculosis. Am. J. Physiol. Lung Cell. Mol. Physiol.
301:L731–L738.
22. Marchant A, et al. 1999. Newborns develop a Th1-type immune response
to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J. Immu-
nol. 163:2249 –2255.
23. Marthas ML, et al. 2011. Partial efficacy of a VSV-SIV/MVA-SIV vaccine
regimen against oral SIV challenge in infant macaques. Vaccine 29:3124 –
3137.
24. Marthas ML, et al. 1995. Viral factors determine progression to AIDS in
simian immunodeficiency virus-infected newborn rhesus macaques. J. Vi-
rol. 69:4198 – 4205.
25. Murray RA, et al. 2006. Bacillus Calmette Guérin vaccination of human
newborns induces a specific, functional CD8 T cell response. J. Immunol.
177:5647–5651.
26. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: the promise and the
challenge. Nat. Rev. Immunol. 6:148 –158.
27. Ota MO, et al. 2002. Influence of Mycobacterium bovis bacillus
Calmette-Guérin on antibody and cytokine responses to human neonatal
vaccination. J. Immunol. 168:919 –925.
28. Ranganathan UD, et al. 2009. Recombinant pro-apoptotic Mycobacte-
rium tuberculosis generates CD8 T cell responses against human immu-
nodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vac-
cine 28:152–161.
29. Rodrigues LC, Diwan VK, Wheeler JG. 1993. Protective effect of BCG
against tuberculous meningitis and miliary tuberculosis: a meta-analysis.
Int. J. Epidemiol. 22:1154 –1158.
30. Sambandamurthy VK, et al. 2006. Mycobacterium tuberculosis DeltaRD1
DeltapanCD: a safe and limited replicating mutant strain that protects immu-
nocompetent and immunocompromised mice against experimental tubercu-
losis. Vaccine 24:6309–6320.
31. Sambandamurthy VK, et al. 2005. Long-term protection against tuber-
culosis following vaccination with a severely attenuated double lysine and
pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun.
73:1196 –1203.
32. Sambandamurthy VK, Jacobs WR, Jr. 2005. Live attenuated mutants of
Mycobacterium tuberculosis as candidate vaccines against tuberculosis.
Microbes Infect. 7:955–961.
33. Sambandamurthy VK, et al. 2002. A pantothenate auxotroph of Myco-
bacterium tuberculosis is highly attenuated and protects mice against tu-
berculosis. Nat. Med. 8:1171–1174.
34. Sampson SL, et al. 2011. Extended safety and efficacy studies of a live
attenuated double leucine and pantothenate auxotroph of Mycobacte-
rium tuberculosis as a vaccine candidate. Vaccine 29:4839 – 4847.
35. Shen Y, et al. 2001. Antiretroviral agents restore Mycobacterium-specific
T-cell immune responses and facilitate controlling a fatal tuberculosis-like
disease in macaques coinfected with simian immunodeficiency virus and
Mycobacterium bovis BCG. J. Virol. 75:8690 – 8696.
36. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood
tuberculous meningitis and miliary tuberculosis worldwide: a meta-
analysis and assessment of cost-effectiveness. Lancet 367:1173–1180.
37. Van Rompay KK, et al. 2010. Immunogenicity of viral vector, prime-boost
SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stoma-
titis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vac-
cines compared to live-attenuated SIV. Vaccine 28:1481–1492.
38. Van Rompay KK, et al. 2003. Immunization of newborn rhesus ma-
caques with simian immunodeficiency virus (SIV) vaccines prolongs sur-
vival after oral challenge with virulent SIVmac251. J. Virol. 77:179 –190.
39. Van Rompay KK, et al. 1992. Simian immunodeficiency virus (SIV)
infection of infant rhesus macaques as a model to test antiretroviral drug
prophylaxis and therapy: oral 3=-azido-3=-deoxythymidine prevents SIV
infection. Antimicrob. Agents Chemother. 36:2381–2386.
40. Van Rompay KK, et al. 2004. The clinical benefits of tenofovir for simian
immunodeficiency virus-infected macaques are larger than predicted by
its effects on standard viral and immunologic parameters. J. Acquir. Im-
mune Defic. Syndr. 36:900 –914.
41. Vekemans J, et al. 2001. Tuberculosis contacts but not patients have
higher gamma interferon responses to ESAT-6 than do community con-
trols in The Gambia. Infect. Immun. 69:6554 – 6557.
42. Waters WR, et al. 2009. Efficacy and immunogenicity of Mycobacterium
bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves. Vac-
cine 27:1201–1209.
43. WHO. 2011. Report on the global HIV/AIDS response. World Health
Organization, Geneva, Switzerland. http://www.who.int/hiv/en/.
44. WHO. 2011. Global tuberculosis control 2011. World Health Organiza-
tion, Geneva, Switzerland. http://www.who.int/tb/publications/global
_report/en/.
45. WHO. 2011. World Health Organization HIV/TB facts 2011. World
Health Organization, Geneva, Switzerland. http://www.who.int/hiv
/topics/tb/hiv_tb_factsheet_june_2011.pdf.
46. WHO. 2007. Meeting of the immunization strategic advisory group of
experts, April 2007— conclusions and recommendations. Revised BCG
Jensen et al.
1180 cvi.asm.org Clinical and Vaccine Immunology
vaccination guidelines for infants at risk for HIV infection. International
Health Regulations. Wkly. Epidemiol. Rec. 82:181–196.
47. Wiseman CA, et al. 2012. A proposed comprehensive classification of tuber-
culosis disease severity in children. Pediatr. Infect. Dis. J. 31:347–352.
48. Zhou D, et al. 1999. Mycobacterium bovis bacille Calmette-Guérin en-
hances pathogenicity of simian immunodeficiency virus infection and ac-
celerates progression to AIDS in macaques: a role of persistent T cell acti-
vation in AIDS pathogenesis. J. Immunol. 162:2204 –2216.
49. Zimmerman DM, et al. 2009. Safety and immunogenicity of the Myco-
bacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats
infected with feline immunodeficiency virus. Clin. Vaccine Immunol. 16:
427– 429.
Pediatric HIV-TB Vaccine Safety in Infant Macaques
August 2012 Volume 19 Number 8 cvi.asm.org 1181
